Drug intelligence / Profile preview

IZN-6NVS

Development stage: Phase 2
Lead developer: Izun Pharma
Modality: Small Molecules
Administration: Vaginal

Overview

IZN-6NVS is an investigational drug developed as a vaginal cream for the treatment of atrophic vaginitis and desquamative inflammatory vaginitis. It has been evaluated in a Phase 1/2 clinical trial to assess its safety, tolerability, and efficacy in women with these conditions. The specific mechanism of action has not been disclosed publicly. The developer is Izun Pharmaceuticals Corp., a company based in New York[1][2].

Beyond the preview

Go deeper on IZN-6NVS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IZN-6NVS.

Explore the full profile